Brentford, United Kingdom
GSK (GlaxoSmithKline) is investing £275 million to expand its pharmaceutical manufacturing capacity at three sites in the United Kingdom. A £92 million aseptic sterile facility will be built at Barnard Castle, and a £110 million plant for the production of respiratory active ingredients will be constructed at Montrose in Scotland. Lastly, GSK will spend £74 million to create additional manufacturing capacity for the Ellipta respiratory inhaler at its Ware campus. GSK's global headquarters are located in Brentford in the United Kingdom.
